Profile for Eurasian Patent Organization Patent: 026251

US Patent Family Members and Approved Drugs for Eurasian Patent Organization Patent: 026251

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,292,954	Aug 31, 2031	Ipsen	SOHONOS	palovarotene
12,023,312	Aug 31, 2031	Ipsen	SOHONOS	palovarotene
9,314,439	Aug 31, 2031	Ipsen	SOHONOS	palovarotene

Detailed Analysis of the Scope, Claims, and Patent Landscape for Eurasian Patent Organization Drug Patent EA026251

Last updated: July 30, 2025

---

Introduction

Patent EA026251, granted by the Eurasian Patent Organization (EAPO), encompasses a pharmaceutical invention with implications for drug development, manufacturing, and therapeutic application. This analysis dissects the scope and claims of the patent, evaluates its positioning within the broader patent landscape, and assesses strategic considerations for stakeholders in the pharmaceutical sector.

---

Overview of Eurasian Patent EA026251

EA026251 was granted to protect a novel drug-related invention, potentially involving a new chemical entity, formulation, or method of use. The Eurasian patent system, governed by the Eurasian Patent Convention (EAPC), offers a centralized patent protection mechanism across member states, including Russia, Armenia, Belarus, Kazakhstan, and Kyrgyzstan.

The patent's filing and grant dates, along with its publication details, suggest its strategic significance in the Eurasian market. Although the detailed documentation is proprietary, publicly available patent databases provide insights into its claims and scope.

---

Scope of the Patent

1. Subject Matter Coverage

The patent likely covers pharmaceutical compounds, compositions, and methods of treatment. Typical scope for drug patents encompasses:

• Chemical compounds: New molecular entities or derivatives.
• Pharmaceutical compositions: Formulations including excipients, delivery vehicles, and stabilizers.
• Methods of use: Therapeutic methods for treating specific diseases or conditions.
• Manufacturing processes: Innovative synthesis routes or purification techniques.

Without access to the full text, the scope presumably spans one or more of these categories, aligned with standard patent protection strategies in pharmaceuticals.

2. Territorial Scope

EA026251 grants protection within Eurasian states, offering regional